News
Sermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
COLUMBUS, Ohio, April 28, 2022 — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical...
Biotech raises $40M to test forgotten osteoporosis drug in treatment-resistant breast cancer
February 07, 2022 06:30am EST | Source: Sermonix Pharmaceuticals LLC A Columbus...
Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium
Poster describes pre-clinical findings that lasofoxifene alone or in combination with a CDK...
Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II
Funds will be used to further advance lasofoxifene through late-stage clinical development as a...
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying …
COLUMBUS, Ohio, June 28, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Preclinical Lasofoxifene Study in Endocrine-Resistant Breast Cancer
Paper highlights the ability of lasofoxifene to inhibit primary tumor growth and reduce metastases...
Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential Effects of Lasofoxifene on ESR1 Mutations in Endometrial Cancer
Preclinical effort will examine effect of lasofoxifene on unique endometrial cancer models...
Sermonix Pharmaceuticals Names Dr. Elizabeth Garner to Its Board of Directors
Garner’s pharma development expertise includes women’s health and gynecologic oncology COLUMBUS,...
Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020
The poster will be made available at SABCS.org on Wednesday, Dec. 9 COLUMBUS, Ohio, Dec. 03, 2020...
To sign up for future Sermonix press releases, please enter your information below.